Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COmModa observational study of Aubagio in relapsing-remitting multiple sclerosis
NL-OMON25460Phase 4Not yet recruiting
- Sponsor
- Sanofi
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of teriflunomide in multiple sclerosis (MS), sponsored by Sanofi. Primary endpoint: Change in cognitive status at 36 months. Planned start Aug 2016; status: not yet recruiting.
02
Drugs
teriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON25460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25460.